Skip to main content
PSMA PET/CT may increase detection of prostate cancer sites

Researchers found that gallium-68 PSMA-11 PET/CT significantly affected the planning of definitive radiotherapy for between 16.5% and 37% of patients with localized prostate cancer. The findings in the Journal of Nuclear Medicine suggest that including PSMA PET/CT in the radiotherapy planning process "might improve the success rate of curative-intent prostate radiotherapy," said researcher Dr. Nicholas Nickols.

Full Story: